A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Cyclo-Z in Subjects With Type 2 Diabetes
Overview
- Phase
- Phase 2
- Intervention
- Cyclo-Z
- Conditions
- Diabetes Mellitus, Type 2
- Sponsor
- NovMetaPharma Co., Ltd.
- Enrollment
- 256
- Locations
- 20
- Primary Endpoint
- Change in Glycosylated Hemoglobin (HbA1c) from Baseline at Week 24
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
This is a double-blind, randomized, placebo-controlled, parallel-group comparison study to evaluate the efficacy and safety of Cyclo-Z vs. placebo in adult subjects with type 2 diabetes. Approximately 20 clinical sites may be utilized in the United States so that approximately 300 subjects (a potential 20% screening failure rate) may be screened for total 28-week study period (2 weeks for screening, 24 weeks for treatment, and 2 weeks for safety follow-up).
Detailed Description
Insulin degrading enzyme (IDE) is a zinc-containing enzyme that regulates degradation of internalized insulin and the maintenance of insulin sensitivity. Diabetic animals and humans are zinc deficient due to impaired intestinal zinc absorption and hyperzincuria. If endosomal IDE levels are inadequate, undigested insulin will remain in the cytosol and prevent insulin signal transduction. Cyclo-Z enhances IDE synthesis and stimulates insulin degradation. Although Cyclo (his-pro) (CHP) or zinc alone are somewhat effective in the control of blood glucose metabolism, based on the available literature and previous background studies, it is hypothesized that the combination of CHP and zinc in Cyclo-Z work synergistically to ameliorate insulin resistance in diabetic and obese subjects mainly by stimulating IDE synthesis.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Males or females aged 18 or older.
- •Subjects diagnosed with type 2 diabetes mellitus (DM) according to the American Diabetes Association (ADA) criteria.
- •Subjects treated with stable doses of insulin and/or other hypoglycemic agent(s) for type 2 diabetes mellitus for at least 2 months prior to randomization and who agree to stay on stable doses of anti-diabetes agents during the study.
- •Subjects whose fasting blood glucose levels are reasonably stable for at least 2 months prior to randomization and during the 2-week screening period.
- •Subjects who have Hemoglobin A1c levels of 7.5 to 10.0 % at Screening and a fasting plasma glucose less than 310 mg/dL.
- •Subjects who can give written informed consent.
- •Subjects who are willing and able to monitor their blood glucose concentrations with a home glucose monitor (before breakfast and 2 hours after dinner).
- •Female subjects must be either:
- •Surgically sterile (i.e., have had bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) at least 6 months before randomization, or
- •Post-menopausal for at least 12 months prior to Screening, or
Exclusion Criteria
- •Subjects who have any significant DM-related end-organ damages.
- •Subjects who have a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma.
- •Subjects who have any disease likely to limit life span and/or increase risks of interventions such as:
- •Carotid B-mode ultrasound test results indicating clinically significant stenosis in the common carotid arteries requiring intervention by angioplasty or resection.
- •Cancer treatment in the past 5 years, with the exception of cancers which have been cured, and carry a good prognosis.
- •Infectious disease: HIV positivity, active tuberculosis, or pneumonia.
- •Subjects with evidence of clinically significant cardiovascular or cerebrovascular disease, including (but not limited to):
- •Hospitalization for the treatment of heart disease in the past 12 months.
- •New York Heart Association Functional Class \>
- •Left bundle branch block on ECG at Screening.
Arms & Interventions
Dose A
Cyclo-Z containing 23 mg zinc plus 6 mg CHP
Intervention: Cyclo-Z
Dose B
Cyclo-Z containing 23 mg zinc plus 15 mg CHP
Intervention: Cyclo-Z
Dose C
Placebo
Intervention: Placebo
Outcomes
Primary Outcomes
Change in Glycosylated Hemoglobin (HbA1c) from Baseline at Week 24
Time Frame: Day 1 to 24 weeks
Change in HbA1c from Day 1 to Week 24
Secondary Outcomes
- Change from Baseline in HbA1c over time(Day 1 to 24 weeks)
- Proportion of subjects with decrease in HbA1c of ≥ 0.5% from Baseline at Week 24(Day 1 to 24 weeks)
- Proportion of subjects with decrease in HbA1c of ≥ 1.0% from Baseline at Week 24(Day 1 to 24 weeks)
- Change from Baseline in fasting plasma glucose (FPG) levels over time(Day 1 to 24 weeks)
- Change from Baseline in plasma insulin over time(Day 1 to 24 weeks)
- Proportion of subjects achieving HbA1c goal of < 7.0% at Week 24(Day 1 to 24 weeks)
- Proportion of subjects achieving HbA1c goal of < 6.5% at Week 24(Day 1 to 24 weeks)